Navigation Links
Cardium Selected for Inclusion in Russell Microcap Index
Date:6/24/2008

angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's Celsius Control System(TM) and the CoolBlue(TM) System, please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Launches New AWARE Clinical Study Website
3. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
4. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
5. Cardium Reports on First Quarter 2008 Highlights and Financial Results
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
8. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
9. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
10. Cardium Completes $5.3 Million Registered Direct Offering
11. Cardium Announces $5.3 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 ... innovative Entwicklungen für Diagnostik und Therapie, Strahlendosismanagement und ... Royal Philips (NYSE: PHG, ... Europäischen Röntgenkongress 2015 (ECR) bekannt, der vom ... stattfindet. An den Ständen Nr. 102 and ...
(Date:3/3/2015)... 2015 Experts and industry insiders from ... event: the Alltech REBELation exploring innovation, inspiration and world-changing ... in its 31st year, Alltech’s annual international conference traditionally ... the opportunity to join the REBELation at an extra ... p.m. EST, at which point the standard early registration ...
(Date:3/3/2015)... March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), ... technologies and products for advanced microarray diagnostics, today ... CFE  to its Management team. In his capacity ... its transition from a development stage to a ... advance the Company,s capital market strategy and to ...
(Date:3/3/2015)... , March 3, 2015  Regenicin, Inc. (OTC Bulletin ... in the development of and commercialization of regenerative cell ... organs, announced today that it has received the final ... Bioscience Holdings, Inc. (OTC Bulletin Board: AMBS ... Amarantus made the final payments due to Regenicin in ...
Breaking Biology Technology:Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 2Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 3Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 4Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 5Philips stellt integrierte Bildgebungslösungen auf dem Europäischen Röntgenkongress 2015 vor 6World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3
... an individual becomes infected with HIV the virus infects ... nervous system [CNS]). Although this causes no immediate problems, ... and encephalitis (acute inflammation of the brain that can ... (SIV) also sometimes develop CNS damage and provide a ...
... A genetic tool used by medical researchers may also be ... viruses from drinking water. , In a series of proof-of-concept ... material could successfully target a matching portion of a gene ... stop working. If this new approach can be perfected, the ...
... Exponent, Inc.,(Nasdaq: EXPO ) announced today ... an additional $35,000,000 for the repurchase of Exponent,s ... transactions in compliance,with Securities and Exchange Commissions Rule ... the future cash flow of the,Company, as well ...
Cached Biology Technology:Possible new approach to purifying drinking water 2Possible new approach to purifying drinking water 3Exponent Adds $35 Million to Stock Repurchase Program 2
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... ,A new EU project, METSY, develops and applies ... metabolism is connected to psychotic disorders and metabolic ... The overall objective is to identify, prioritize and ... diagnostic potential for prediction and monitoring psychotic disorders ...
... by ChipCare Corporation, has secured one of the ... Phase II financing has closed, with an investment ... commercialization over the next three years. The ... among Canadian social angel investors, including Maple Leaf ...
... of Geneva (UNIGE),s Faculty of Medicine in the context of ... the genetic causes of differences between people. The study, published ... the largest-ever dataset linking human genomes to gene activity at ... genome makes them more or less susceptible to disease is ...
Cached Biology News:ChipCare's handheld analyzer attracts one of Canada's largest-ever healthcare angel investments 2Functional genetic variation in humans: Comprehensive map published 2
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
... Mouse monoclonal antibody raised against ... Immunogen: HD ... a.a) partial recombinant protein with ... Accession Number: NM_002111 ...
Biology Products: